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ABSTRACT
Hematopoietic stem cell transplantation (HSCT) is an integral part of the treatment of many patients with acute
myeloid leukemia (AML). Despite extensive study, the appropriate role and timing of allogeneic and autologous
transplantation in AML are poorly defined. This review critically analyzes the extensive literature, focusing on
the recent advances, and provides practical recommendations for the use of HSCT in AML.
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Acute myeloid leukemia (AML) is currently the
most common indication for allogeneic hematopoietic
stem cell transplantation (HSCT), and also accounts
for a large proportion of autologousHSCT [1].Despite
numerous studies, the use and timing of allogeneic and
autologous transplantation in AML vary widely, and
many important questions remain unresolved. At the
same time,modifications of supportive care and prepar-
ative regimens continue to improve results and extend
the application of HSCT in AML. We review here
the theory of HSCT in AML, critically analyze the
vast literature on its use, and make recommendations
for clinical practice.
THEORETIC BASIS FOR ALLOGENEIC TRANSPLANTATION
IN AML
The observation that animals given lethal doses of
total-body irradiation (TBI) were protected from death
by infusion of autologous [2], syngeneic [3], or allo-
geneic marrow [4] led to human studies in acute leuke-
mia.Thomas andcolleagues [5] hypothesized that lethal
doses of TBI and cyclophosphamide could destroy
leukemic cells, normalmarrow, and the immune system
556of patients with leukemia, and that infusion of normal
marrow from allogeneic histocompatible donors would
rescue them. Thomas’s early studies in end-stage
leukemias confirmed their hypothesis and established
a new therapy. Althoughmany advances have occurred,
Thomas’s [5,6] original clinicalworkmore than30years
ago achieved results remarkably similar to those
achieved today.
It is now understood that AML consists of a hier-
archy of cells derived from rare leukemia stem cells,
which retain the unique capacity for self-renewal [7].
Leukemic stem cells replenish the bulk population of
leukemic cells that possess only limited potential for
proliferation. Leukemic stem cells sustain and pro-
pagate human leukemia. They are exceedingly rare: as
few as 1 in 1 million leukemia cells may be capable of
initiating and sustaining leukemia in immunologically
susceptible mice [8].
Like normal hematopoietic stem cells, leukemic
stem cells are quiescent and resistant to chemothe-
rapeutic agents, which are most effective in proliferat-
ing cells. They excrete toxic drugs by ATP-binding
transporters and repair DNA injury efficiently. Leuke-
mic stem cells, therefore, are generally not affected by
conventional chemotherapy [9]. Virtually all patients
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and complete remission following induction chemo-
therapy will relapse as a result of undetectable residual
leukemic stem cells if additional treatment is not given.
‘‘Lethal’’ doses ofTBI or drugs, for example, busul-
fan, destroy blast cells andmay eliminate leukemic stem
cells in a minority of cases, but the high relapse rate
following syngeneic transplantation suggests that a graft-
versus-leukemia (GVL)effect is required for eradication
of leukemia in most patients [10]. The development of
complete donor hematopoietic chimerism following
nonmyeloablative preparative regimens demonstrates
the capacity of donor immune cells to eradicate nor-
mal hematopoietic stem cells. Immunologically active
donor T cells can also eliminate human acute myeloid
leukemia stemcells, preventing the experimental devel-
opment of human AML in mice [11] and curing AML
in humans [12].
If the immunologic effect is of primary importance
in eradication of leukemic stem cells, nonablative
regimens designed to permit engraftment of donor
immune cells with minimal toxicity would seem a wise
strategy. Although patients with large blast burdens
may not be susceptible to this approach because of
rapid progression of disease, its apparent effectiveness
in some patients lends credence to this theory.
THEORETIC BASIS FOR (AND AGAINST) AUTOLOGOUS
TRANSPLANTATION
Autologous transplantation is limited by contami-
nation of the stem cell product by malignant cells and
the absence of an immunologic effect of allogeneic
cells. Clinical results reveal less curative potential for
autotransplantation than for syngeneic transplantation
and less for syngeneic than for allogeneic trans-
plantation, suggesting that both of these limitations
are operative. Still, autologous transplantation cures
some patients. Thus, in some instances, high-dose pre-
parative therapy must eradicate leukemic stem cells,
and the stem cell graft must not contain leukemic
stem cells capable of engrafting [13] and giving rise
to AML.
CLINICAL RESULTS
Allogeneic Transplantation in First Complete
Remission (CR)
Treatment with an anthracycline and cytarabine
achieves CR in 60%-80% of adults\60 years of age
with newly diagnosed AML [14], but virtually all
patients relapse without further treatment [15,16].
Options for postremission therapy include allogeneic
HSCT, autologous HSCT, and consolidation chemo-
therapy. Thomas and coworkers [6] pioneered the use
of HLA (human leukocyte antigen)-identical sibling
donor marrow transplantation for patients with AML
in first CR, achieving sustained leukemia-free survival(LFS) inmore than half. Prospective studies comparing
allogeneic HSCT with consolidation chemotherapy in
the 1980s and early 1990s (Table 1) showed lower
relapse rates in patients who underwent allogeneic
HSCT, but higher treatment-relatedmortality (TRM)
and no survival advantage [17-19].
Since 1995, 6 cooperative group trials have exam-
ined the role of HSCT in AML in first remission
(Table 1) [20-25]. Patients with HLA-identical sibling
donors were offered allogeneic transplantation (‘‘ge-
netic randomization’’), whereas others were generally
randomized between autologous transplantation and
intensive consolidation chemotherapy (ICC). Lower
relapse rates in patients undergoing allogeneic
HSCT conferred improved or equivalent LFS and
similar survival compared to ICC.
Autologous Transplantation in First Remission
Although favorable results for autologous trans-
plantation in patients with AML in first CR have
been reported, there is no definitive data indicating
that this approach is superior to ICC. In the Groupe
Ouest Est Leuemieres Aigues Myeloblastiques (GOE-
LAM) trial, in which the ICC group received high
doses of cytarabine (HiDAC), which provides more ef-
fective consolidation than standard doses of cytarabine
[26], there was no benefit in LFS for autotransplant
compared to ICC [23], similar to the US intergroup
trial [22]. Two separate meta-analyses of 6 randomized
studies demonstrated that autologous bone marrow
transplantation modestly prolonged event-free sur-
vival (EFS) but not overall survival (OS) compared to
consolidation chemotherapy or no further treatment
in adults with AML in first CR [27,28]. Because auto-
transplantation in first CR provides no clear advantage
over chemotherapy, its routine use is unwarranted and
shortsighted because it jeopardizes the safety and
effectiveness of subsequent allogeneic transplantation
in those who relapse and are candidates for this
procedure.
Cytogenetics and Other Risk Factors
An assortment of factors that influence outcome
following treatment with chemotherapy alone or
with transplantation have been identified. The factors
that are critical to determining the best treatment in an
individual are those that differentially affect the results
of transplantation and consolidation chemotherapy.
Analysis of several SouthwestOncologyGroup (SWOG)
studies showed that older age adversely affected trans-
plant outcome more than chemotherapy outcome, and
that higher white blood cell count at diagnosis and a
requirement for more than 1 induction cycle to achieve
remission adversely affected chemotherapy outcome
but not transplant outcome [29,30]. AML related to
prior therapy, after accounting for cytogenetics, is
558 M. Hamadani et al.Table 1. Prospective Trials Evaluating Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission
No. of Patients Relapse Rate (%) Leukemia-Free Survival (%) Overall Survival (%)
Author (Reference)
Year (Cooperative
Group) Design Allo Auto C Allo Auto C Allo Auto C Allo Auto C
Appelbaum [18] 1984 Allo versus C 33 — 46 NR — NR 49 — 20 NR — NR
Champlin [17] 1985 Allo versus C 23 — 44 40 — 71 NR — NR 40 — 27
Archimbaud [19] 1994 Allo versus C 27 — 31 43 — 67 41 — 27 41 — 46
Zittoun [20] 1995
(EORTC/GIMEMA
AML-8)
Allo versus C
versus Auto
168 128 126 24 41 57 55 48 30 59 56 46
Harousseau [23] 1997
(GOELAM)
Allo versus C
verus Auto
73 75 71 37 45 55 49 48 43 55 52 58
Cassileth [22] 1998
(ECOG/CALGB/
SWOG)
Allo versus C
versus Auto
113 116 117 29 48 61 43 34 34 46 43 52
Burnett [21] 1998
(MRC AML-10)
Auto versus
no further
treatment
— 190 191 — 37 58 — 53 40 — 57 45
Suciu [24] 2003
(EORTC/GIMEMA
AML-10)
Allo versus Auto 293 441 — 30 52 — 52 42 — 58 50 —
Cornelissen [25] 2007
(HOVON-SAKK)
Donor versus
no donor
326 165 398 †32 †59 †48 †37 †54 †46
Allo indicates allogeneic; auto, autologous; C, chemotherapy; NR, not reported.
Relapse rates, disease-free survival and overall survival shown above are at 4 years with the following exceptions. 1.Leukemia free survival
reported by Appelbaum et al. is at 5years. 2. Relapse rate and leukemia-free survival reported by Archimbaud is at 7years. 3. Leukemia
free and overall survival reported by Burnett et al. is at 7years.
†In HOVON-SAKK study relapse rate, disease-free survival and overall survival of patients getting chemotherapy or autologous-HSCT is (not
provided separately, rather it is) reported together as ‘‘no donor’’ group.not associated with an adverse prognosis following
allogeneic transplantation [31,32] as it is with chemo-
therapy alone [33].
Genetics largely determines the biologic behavior
of AML and is the most powerful prognostic factor
[34,35]. Specific genetic abnormalities affect results
achieved with ICC and transplantation differentially.
Patients with favorable cytogenetics producing aber-
rant core binding factor, including inversion (16), and
translocation(8;21) fare better with HiDAC consoli-
dation. The North American Intergroup trial [22],
stratified according to cytogenetic risk [36], showed
superior 5-year survival for patients with unfavorable
cytogenetics who underwent allogeneic transplanta-
tion (44%) compared to autologous transplantation
(13%) or ICC (15%). Meta-analysis of randomized
studies confirmed the OS benefit of allogeneic HSCT
for patients with poor-risk cytogenetics (coefficient of
10.24 on metaregression analysis) and suggested im-
proved OS in the intermediate-risk group (coefficient
of 10.09) [37].
The recent Dutch-Belgian Hemato-Oncology
Co-operative Group (HOVON) and Swiss Group
for Clinical Cancer Research (SAKK) trial demon-
strated superior LFS with allogeneic HSCT for both
intermediate and poor-risk groups [25]. Risk stratifica-
tion included induction cycles needed to achieve CR,and white cell count, in addition to cytogenetics.
Meta-analysis of 4 cooperative group (including the
HOVON-SAKK study) trials of 4000 AML patients
in CR1 demonstrated a 12% OS benefit at 4 years
for patients with poor or intermediate risk cytogenet-
ics who had an HLA-identical donor. Allogeneic
HSCT was superior for patients whose apparent risk
of relapse with ICC exceeded 35% [25].
Patients with intermediate-risk cytogenetics fare
better with high-dose cytarabine consolidation than
with standard doses [34]. The role of HLA-identical
sibling transplantation in patients in first remission
with intermediate-risk cytogenetics remains contro-
versial. Genetic abnormalities undetectable with stan-
dard cytogenetic analyses can be used to segregate the
nearly 50% of patients with normal cytogenetics into
less favorable (partial tandem duplications of MLL
gene, FLT3 internal tandemduplications [FLT3-ITD],
high expression of BAALC) [38-40] or more favorable
risk (nucleophosmin [NPM1] or CEBP-alpha tran-
scription factor gene point mutation) [41,42] groups.
Analysis of 4 trials assigning patients with normal cyto-
genetics and anHLA-matched sibling donor to alloge-
neic transplantation in first CR showed that patients
whose leukemia wasNPM11 /FLT3-ITDhad no im-
provement inOS or LFSwith transplantation, whereas
patients with other combinations more than doubled
HSCT in Adults with AML 559their 4-year LFS with allogeneic-HSCT (47% versus
23%) [43]. Although further study is needed, these
genetic aberrations are detectable by commercially
available tests, and their apparent prognostic impact
justifies their use in combination with other factors
to help determine treatment in selected patients.
It is critical to recognize the limitations of the com-
parative trials. They employ ‘‘genetic randomization’’
and are not truly randomized. Many use consolidation
regimens that are inferior to HiDAC in favorable and
intermediate-risk groups. The studies use intent-to-
treat analyses, but have high ‘‘dropout’’ rates (except
in the HOVON-SAKK trial where compliance was
82%) of patients randomized to receive an allograft
[44], underestimating the effect of HSCT. Analysis
by cytogenetic risk categories is confounded by small
numbers of patients: individuals with poor-risk cytoge-
netics assigned to allogeneic-HSCT inMRCAML-10,
SWOG/ECOG, EORTC/GIMEMA AML-10, and
HOVON-SAKK were 13, 18, 64, and 36, respectively.
Last, induction and consolidation chemotherapy, trans-
plantation preparative regimens, graft-versus-host dis-
ease (GVHD) prophylaxis, supportive care measures,
and even cytogenetic risk categories (Table 2) are not
uniform, complicating comparisons and summari-
zations.
Unrelated Donor Transplantation in First CR
Less than 30% of patients have an HLA-identical
sibling donor [45]. Adult matched unrelated donor
(URD) or cord blood transplantation are options in
patients lacking sibling donors. Approximately 11million HLA-typed volunteer donors are currently
registered in the Bone Marrow Donors Worldwide
file (www.bmdw.org). The probability of finding an
HLA-A, -B, -C, -DR, and –DQmatch by high-resolu-
tion DNA typing is 35%-40% for a Caucasian [46] and
less for some minorities. Recent reports show similar
rates of acute GVHD (aGVHD), TRM, relapse rate,
and OS in patients with standard-risk hematologic
malignancies undergoing HLA-identical sibling
transplantation compared to HLA-allelic-matched
URD (10 of 10) transplantation [47,48]. The risk of
GVHD, graft failure, and mortality increases with an
increasing number of HLA disparities between the
recipient and donor [49], and disparities are tolerated
more poorly by older patients. In a series of 161
patients in first CR treated with variably matched
unrelated transplants, the 5-year LFS was 50% [50].
High graft cell doses and CMV seronegativity were
favorable prognostic factors.
The 5-year OS for patients with unfavorable cyto-
genetics undergoing URD transplantation in CR1 was
30% in a CIBMTR/NMDP (National MarrowDonor
Program) study [51], which compares favorably with
survival rates below 15% reported for such patients
with autologous-HSCT or ICC [36]. The German
AML 01/99 trial prospectively studied patients with
AML in first CR at high risk for relapse based on
unfavorable cytogenetic abnormalities or more than
5% blasts on day 15 marrow. Four-year survival was
68%, 56%, and 23%, respectively, for those who
underwent sibling, unrelated, and autologous trans-
plantation (P \ .01) [52]. URD transplantation isTable 2. Comparison of Cytogenetic Risk Group Definitions
Cytogenetic Risk Groups
Study Good Intermediate Poor
ECOG/SWOG  inv16, t(16;16), 16q-
 t(8;21) without -9q and CK
 t(15;17)
 NN
 18
 16
 -Y
 del(12p)
 -5/5q-
 -7/7q-
 t(6;9)
 t(9;22)
 abnormal 3q, 9q, 11q, 20q, 21q, and 17p
 CK
MRC AML-10 [95]  inv16, t(16;16), 16q-
 t(8;21)
 t(15;17)
 All other cytogenetic
abnormalities
 -5/5q-
 -7
 abnormal 3q
 t(6;9)
 t(9;22)
 CK
EORTC/GIMEMA AML-10  t(8:21)
 inv16, t(16;16), 16q-
 NN
 -Y
 All other cytogenetic
abnormalities
HOVON-SAKK  t(8:21)
 inv16, t(16;16), 16q-
 All other cytogenetic
abnormalities
 -5/5q-
 -7/7q-
 abnormal 3q
 t(6;9)
 t(9;22)
 abn(11q23)
 CK
CK indicates complex karyotype; NN, normal karyotype.
560 M. Hamadani et al.appropriate for younger patients with AML in CR1
with high-risk cytogenetics. Transplantation using well-
matched URD might also be considered for selected
patients with normal cytogenetics and unfavorable
genetic abnormalities or otherwise at high risk for
relapse who lack significant comorbidities.
Umbilical Cord Blood Transplantation (UCBT)
The easy and rapid availability of a prescreened,
HLA-typed product makesUCBT an attractive option
for patients without a HLA-matched sibling or adult
unrelated donor. Transplantation using cord blood is
associated with lower GVHD rates for the degree of
HLA-mismatching. UCBT is an appropriate alterna-
tive when a well-matched URD is not available within
a reasonable time [53-58]. Limited experience with
UCBT and the low stem cell dose available from indi-
vidual cord units has limited the use of UCBT in adults
with AML, but the use of multiple units from different
donors may improve engraftment [58]. Expansion of
the current pool of cord blood units could markedly
extend the application of transplantation, particularly
to minority populations underrepresented in adult
registries.
Comorbidities
Although the role of genetics and other factors in
predicting the behavior of AML have received consid-
erable attention, factors that determine the risk of
TRM have received less emphasis, but are of at least
equal importance. Older age and poor performance
status are appropriately used in patients in first CR
to select consolidation chemotherapy over allogeneic
transplantation where the adverse risk of these factors
is magnified. But systematic assessment of comorbid-
ities is rare [59]. The hematopoietic cell transplanta-
tion comorbidity index, developed by Sorror and
colleagues [60,61], is the most influential risk factor
for nonrelapse mortality and survival in patients with
AML in first CR who undergo allogeneic transplan-
tation. Evaluation and scoring take\10 minutes. The
same index has predictive value for chemotherapy-
treatment of AML [62] and for reduced intensity
transplantation [63]. It should be used to estimate
treatment-related risk and to guide decisions on treat-
ment. The judgment to perform allogeneic transplan-
tation in first remission must balance the increased
risk of TRM with transplantation against the extent
to which transplantation decreases the risk of relapse
in an individual patient. The potential for delayed
complications, particularly chronic GVHD (cGVHD),
following transplantation is also an important consid-
eration. Most transplantation survivors, however, are
healthy and active.Allogeneic Transplantation for Primary Refractory
AML
For the approximately 30% of patients with AML
who fail to achieve CR with standard induction
chemotherapy, allogeneic HSCT is the lone curative
option [64]. Table 3 illustrates the outcome of trans-
plantation in studies containing at least 50 patients
with primary induction failure [65-69]. Patient charac-
teristics and inclusion criteria are heterogenous, and
the number of failed induction chemotherapies varies.
The 3-year LFS is approximately 20% to 30%. Favor-
able prognostic factors include availability of an HLA-
identical sibling [66,67], good performance status [66],
young age [66], fewer cycles of induction chemother-
apy [65,69], good-or intermediate-risk cytogenetics
[67], and low tumor burden [65,69]. It is essential to
consider allogeneic transplantation early in the course
of patients who do not achieve remission with initial
therapy.
Transplantation for AML beyond First Remission
Chemotherapy offers little chance of cure for AML
patients who relapse. Despite higher rates of TRM and
relapse and substantially lower LFS [46] than trans-
plantation in first CR, allogeneic HSCT still provides
the best prospect for cure [70,71]. For patients who
previously underwent autologous or allogeneic HSCT
in first remission, however, the likelihood of successful
allografting is markedly reduced [70].
Patients in first relapse nearly always receive
chemotherapy in an attempt to achieve second CR.
The 3-year LFS, however, was nearly 30% in 2 studies
of transplantation in untreated first relapse [72,73].
Because less than half of those who undergo reinduc-
tion therapy will obtain second CR, where allotrans-
plantation is curative in only about 30%, more
patients might be cured with allotransplantation in
early relapse. Candidates for allotransplantation who
are not transplanted in first CR should have early
identification of potential donors to permit timely
transplantation at relapse. They should have their
blood counts monitored closely and undergo marrow
examination for abnormal counts, permitting some
to undergo allotransplantation in untreated early
relapse. For those with sibling donors, rapid transplan-
tation can often be accomplished. Matched URD
usually require months for identification and procure-
ment, but initial survey of URD can speed this process
in patients who do not undergo allogeneic transplanta-
tion in first CR. Patients lacking potential donors can
have autologous stem cells procured while in first
remission.
The 5 year LFS of patients undergoing URD
HSCT in CR1 and CR2, at Fred Hutchinson Cancer
Center were 50% and 28%, respectively [50]. Results
of URD transplantation in patients not in remission
HSCT in Adults with AML 561Table 3. Retrospective Studies Looking at Allogeneic Stem Cell Transplantation for Primary Refractory AML
Author
(Reference)
No. of
Patients
Disease
Burden (% Blasts
in Marrow)
No. of Prior
Regimens
Donor
Type
Leukemia-Free
Survival
Overall
Survival Relapse Rate
Treatment-Related
Mortality
Biggs [65] 88 25% $2* 100% mSib 21% at 3 years NR 62% at 3 years 44%
Michallet [66] 69 NR NR mSib
mmSib
MUD
mMUD
9% at 5 years 13% at 5 years NR 51%
Fung [67] 68 36% #2 (82%)
.2 (18%)
79% mSib
10% MUD
7% mMUD
31% at 3 years 30% at 3 years 51% NR†
Esteve [68] 346 NR NR 100% mSib 18% at 2 years 25% at 2 years 57% at 2 years 25%
Wong [69] 53 23% NR mSib
mmSib
MUD
26% at 2 years 29% at 2 years NR 62%
mSib indicates HLA-identical sibling donor; mmSib, 1 antigen mismatched related donor; MUD, matched unrelated donor; mMUD,
mismatched unrelated donor; NR, not reported; TRM, treatment-related mortality; CR, complete remission.
*Data available for 55 patients only.
†Study claimed TRM comparable to figures with allogeneic transplant in first CR, but no figures were provided.are significantly affected by disease burden (bone mar-
row blasts .20%, blasts in peripheral blood .5000/
mL, or both) and number of prior treatments [50,74].
Patients with advanced disease who do not achieve
remission with salvage chemotherapy experience TRM
rates approaching 50% and only 10%-15% achieve
sustained LFS with allotransplantation [75].
Autologous Transplantation in Second CR
Autologous HSCT results in sustained LFS in
selected patients in second or subsequent CR [76-78].
EBMT registry data demonstrate sustained LFS in
35% of patients undergoing autologous HSCT in sec-
ond CR [78]. Longer duration of CR1, M3 subtype,
grafts harvested in CR1, and younger patient age are
associated with improved survival [76-78]. Patient
selection appears to be largely responsible for the
favorable results obtained in many trials of autologous
transplantation. Among 741 patients (enrolled inMRC
AML 10 and 12 trials) who achieved a second CR, 480
underwent HSCT (116 5 sibling allogeneic trans-
plants, 192 5 autograft, and 154 5 matched URD).
The 5-year OS of patients undergoing HSCT was
superior to those receiving further chemotherapy
(39%versus 22%).The5-year survival rates for patients
undergoing sibling, URD, and autologous transplanta-
tions were 54%, 40%, and 33%, respectively [79].
Reduced-Intensity Conditioning (RIC)
RIC limits the toxicity and lowers the transplant-
related mortality of allogeneic transplantation. Most
RIC studies in AML are retrospective or nonrandom-
ized prospective series, and include heterogeneous
patients (often including some with myelodysplastic
syndromes). Information on cytogenetics is unfortu-
nately limited. Table 4 lists the studies utilizing RICregimens in AML (and MDS) patients that included
at least 50 patients.
No prospective, randomized trials comparing
myeloablative (MA) with RIC regimens in AML have
been performed; however, retrospective comparisons
have been reported [80,81]. The Acute Leukemia
Working Party of EBMT [81] used registry data to
compare 315 recipients of RIC with 407 patients
who receivedMA conditioning prior toHLA-matched
sibling allografts. Over 70% of patients were in CR1 or
CR2. At 2 years, TRM was significantly lower (18%
versus 36%), but relapse rates significantly higher
(41% versus 24%) in the RIC group. LFS and OS
were not significantly different. For patients, mostly
in first or second CR, who received a matched related
or URD allograft following RIC, Hegenbart reported
a relapse rate of 39%, LFS of 44%, andOS of 48% at 2
years. TRM was significantly higher in the URD
group (22% versus 10%) [82].
Seventy percent of patients with AML are over the
age of 55 years [83] and are at high risk of TRM with
ablative allogeneic transplantation. Although RIC
studies have included many elderly patients, they
have also included younger patients with and without
compromised organ function. Table 5 lists those stud-
ies where the median age was .60 years. Alyea et al.
[80] detected no significant difference in LFS and
OS at 2 years in a RIC group (20% and 28%) com-
pared to a myeloablative group (31% and 34%) in
a retrospective comparison of 152 patients older than
50 years. Hegenbart et al. [82] demonstrated that
2-year OS and LFS, in patients over the age of 60 years
(45% and 42%) was similar to that of the whole cohort
of patients aged 17 to 74 years.
In general, patients older than 60 years show lower
TRM and similar OS and LFS compared to those
Table 4. Studi
Author (Y
(Referen (%)
Leukemia-Free
Survival (%)
Overall
Survival (%) TRM (%)
Sayer (2003) [ 29 (2 years) 32 (2 years) 53 (2 years)
de Lima (2004 32 (3 years) 35 (3 years) 30 (1 year)
Ho (2004) [98 -MUD 61-MRD59-MUD
(1 year)
73-MRD71-MUD
(1 year)
5-MRD
21-MUD (1yr)
Van Besien (2 38 (2 years) 39 (2 years) 33 (2 years)
Aoudjhane (2 40 (2 years) 47 (2 years) 18 (2 years)
Tauro (2005) 37 (3 years) 41 (3 years) 19-MRD
24-MUD
(1 year)
Martino (2006 33 (3yrs) 41 (3 years) 22 (3 years)
Hegenbart (2 44 (2 years) 48 (2 years) 16 (2 years)
MRD indicate ted donor; NR, not reported; TRM, tansplant-related mortalityl;
CR, comp th); TBI, total-body irradiation.
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r.undergoing MA conditioning [63,84-86]. Follow-up,
however, is too short to fully evaluate late TRM and
relapse. RIC regimens seem a reasonable option in
older patients in remission who have significant co-
morbidities. These older patients have poor prognoses
with ICC. They should be enrolled on well-designed
clinical trials. Specific criteria to identify patients likely
to fare better with RIC regimens must be established.
The Future
No simple algorithm is sufficient to determine
treatment in individual patients. Attention to the cu-
mulative risk of multiple comorbidities can improve
patient selection for transplantation. Better identifi-
cation and characterization of the entirety of genetic
abnormalities will improve risk stratification. For ex-
ample, the impact of FLT3-ITDon survival in patients
with a normal karyotype depends not merely on its
presence but on the ratio of mutant to wild-type
FLT3 [87]. The KIT-D816 mutation does not appear
to influence survival in patients with a normal karyo-
type, but has a negative impact on survival in patients
with t(8;21) where it occurs more commonly [88].
Methods such as high resolution single nucleotide
polymorphisms arrays identifies previously unrecog-
nized genetic lesions that will almost certainly be clin-
ically relevant [89]. More meaningful characterization
of the biologic behavior of an individual’s leukemic
cells might require more sophisticated methods such
as gene expression profiling [90] or techniques desig-
ned to identify differences in signaling biology [91].
Advances in immunophenotyping and cell separation
[92] may permit the characterization of signaling
pathways in leukemic stem cells [91], providing targets
in the only cells capable of maintaining the leukemia
hierarchy.
The ultimate goal of such work is to systemically
administer agents that selectively eradicate leukemic
stem cells and spare normal hematopoietic stem cells.
More immediately, the use of agents that can be used
in vitro to selectively eradicate leukemic stem cells,
while sparing normal hematopoietic stem cells [93],
could improve autotransplantation. Agents that can
be administered systemically to effectively kill both
normal and leukemic stem cells [94] would require
allogeneic or autologous (purged) rescue. These and
other applications of basic work would make HSCT
more effective in a broader range of patients.
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